PharmiWeb.com - Global Pharma News & Resources
14-May-2025

Lundbeck raises financial guidance following strong start to the year with strategic brands growth of +24% CER

Lundbeck has reported a strong start to 2025, leading the company to raise its full-year financial guidance. This performance is primarily driven by significant growth in its strategic brands, particularly Rexulti® and Vyepti®, across all key geographical regions. The company is also making substantial investments in its R&D pipeline, with key late-stage assets like bexicaserin and amlenetug progressing according to plan. While overall profitability is strong, reflected in increased EBITDA margins, the company is facing higher administrative and R&D costs, as well as increased net financial expenses due to recent acquisition-related debt. Legal proceedings and environmental remediation efforts continue to be managed.